Does the media favor MD or FLGT?

In the previous week, Fulgent Genetics had 2 more articles in the media than Pediatrix Medical Group. MarketBeat recorded 3 mentions for Fulgent Genetics and 1 mentions for Pediatrix Medical Group. Fulgent Genetics' average media sentiment score of 1.62 beat Pediatrix Medical Group's score of 0.47 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pediatrix Medical Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to FLGT or GRDN?

In the previous week, Guardian Pharmacy Services had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Guardian Pharmacy Services and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.62 beat Guardian Pharmacy Services' score of 0.04 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Guardian Pharmacy Services 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, PGNY or FLGT?

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.63 $58.52M $0.92 29.73 Fulgent Genetics $323.93M 1.74 -$60.51M -$2.82 N/A

Is PGNY or FLGT more profitable?

Progyny has a net margin of 6.00% compared to Fulgent Genetics' net margin of -26.05%. Progyny's return on equity of 15.98% beat Fulgent Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% Fulgent Genetics -26.05% -4.93% -4.50%

Does the media favor PGNY or FLGT?

In the previous week, Progyny had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 6 mentions for Progyny and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.62 beat Progyny's score of 1.06 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor AGL or FLGT?

In the previous week, Agilon Health had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 5 mentions for Agilon Health and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.62 beat Agilon Health's score of 0.61 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilon Health 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Fulgent Genetics (FLGT) Competitors

$20.45 +0.33 (+1.64%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$20.45 +0.00 (+0.02%)

As of 09/11/2026 07:30 PM Eastern

Compare

FLGT vs. MD, ASTH, GRDN, PGNY, and AGL

Should you buy Fulgent Genetics stock or one of its competitors? Fulgent Genetics's main competitors and comparable companies include Pediatrix Medical Group (MD), Astrana Health (ASTH), Guardian Pharmacy Services (GRDN), Progyny (PGNY), and Agilon Health (AGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Fulgent Genetics compare to Pediatrix Medical Group?

Pediatrix Medical Group (NYSE:MD) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

97.7% of Pediatrix Medical Group shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 1.8% of Pediatrix Medical Group shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pediatrix Medical Group has a net margin of 8.96% compared to Fulgent Genetics' net margin of -26.05%. Pediatrix Medical Group's return on equity of 20.05% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pediatrix Medical Group	8.96%	20.05%	8.15%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Pediatrix Medical Group currently has a consensus price target of $26.60, indicating a potential downside of 0.78%. Fulgent Genetics has a consensus price target of $27.50, indicating a potential upside of 34.47%. Given Fulgent Genetics' higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Pediatrix Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pediatrix Medical Group	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Fulgent Genetics had 2 more articles in the media than Pediatrix Medical Group. MarketBeat recorded 3 mentions for Fulgent Genetics and 1 mentions for Pediatrix Medical Group. Fulgent Genetics' average media sentiment score of 1.62 beat Pediatrix Medical Group's score of 0.47 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pediatrix Medical Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pediatrix Medical Group has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Pediatrix Medical Group has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Pediatrix Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pediatrix Medical Group	$1.91B	1.14	$165.39M	$2.09	12.83
Fulgent Genetics	$323.93M	1.74	-$60.51M	-$2.82	N/A

Summary

Pediatrix Medical Group beats Fulgent Genetics on 9 of the 15 factors compared between the two stocks.

How does Fulgent Genetics compare to Astrana Health?

Astrana Health (NASDAQ:ASTH) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Astrana Health has a net margin of 1.05% compared to Fulgent Genetics' net margin of -26.05%. Astrana Health's return on equity of 10.30% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrana Health	1.05%	10.30%	3.67%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Astrana Health presently has a consensus target price of $49.43, indicating a potential upside of 30.14%. Fulgent Genetics has a consensus target price of $27.50, indicating a potential upside of 34.47%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Astrana Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrana Health	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Astrana Health has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

52.8% of Astrana Health shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 20.3% of Astrana Health shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Fulgent Genetics had 2 more articles in the media than Astrana Health. MarketBeat recorded 3 mentions for Fulgent Genetics and 1 mentions for Astrana Health. Astrana Health's average media sentiment score of 1.89 beat Fulgent Genetics' score of 1.62 indicating that Astrana Health is being referred to more favorably in the media.

Company	Overall Sentiment
Astrana Health	Very Positive
Fulgent Genetics	Very Positive

Astrana Health has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrana Health	$3.18B	0.67	$22.49M	$0.82	46.32
Fulgent Genetics	$323.93M	1.74	-$60.51M	-$2.82	N/A

Summary

Astrana Health beats Fulgent Genetics on 11 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Fulgent Genetics (NASDAQ:FLGT) and Guardian Pharmacy Services (NYSE:GRDN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Guardian Pharmacy Services has a net margin of 4.50% compared to Fulgent Genetics' net margin of -26.05%. Guardian Pharmacy Services' return on equity of 29.97% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
Guardian Pharmacy Services	4.50%	29.97%	16.18%

In the previous week, Guardian Pharmacy Services had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 4 mentions for Guardian Pharmacy Services and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.62 beat Guardian Pharmacy Services' score of 0.04 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Guardian Pharmacy Services	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

48.1% of Fulgent Genetics shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Guardian Pharmacy Services has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$323.93M	1.74	-$60.51M	-$2.82	N/A
Guardian Pharmacy Services	$1.45B	1.51	$49.22M	$1.03	42.55

Fulgent Genetics presently has a consensus price target of $27.50, suggesting a potential upside of 34.47%. Guardian Pharmacy Services has a consensus price target of $43.83, suggesting a potential upside of 0.01%. Given Fulgent Genetics' higher possible upside, equities analysts plainly believe Fulgent Genetics is more favorable than Guardian Pharmacy Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Guardian Pharmacy Services	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Fulgent Genetics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Guardian Pharmacy Services has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market.

Summary

Guardian Pharmacy Services beats Fulgent Genetics on 10 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Progyny?

Progyny (NASDAQ:PGNY) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Progyny has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

94.9% of Progyny shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 9.9% of Progyny shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Progyny has a net margin of 6.00% compared to Fulgent Genetics' net margin of -26.05%. Progyny's return on equity of 15.98% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Progyny presently has a consensus target price of $34.36, indicating a potential upside of 25.64%. Fulgent Genetics has a consensus target price of $27.50, indicating a potential upside of 34.47%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Progyny had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 6 mentions for Progyny and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.62 beat Progyny's score of 1.06 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.63	$58.52M	$0.92	29.73
Fulgent Genetics	$323.93M	1.74	-$60.51M	-$2.82	N/A

Summary

Progyny beats Fulgent Genetics on 13 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Agilon Health?

Agilon Health (NYSE:AGL) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Agilon Health has a net margin of -3.92% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilon Health	-3.92%	-119.38%	-16.85%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

In the previous week, Agilon Health had 2 more articles in the media than Fulgent Genetics. MarketBeat recorded 5 mentions for Agilon Health and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.62 beat Agilon Health's score of 0.61 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilon Health	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Agilon Health has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Agilon Health currently has a consensus price target of $97.70, indicating a potential upside of 9.05%. Fulgent Genetics has a consensus price target of $27.50, indicating a potential upside of 34.47%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilon Health	2 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.21
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.1% of Fulgent Genetics shares are owned by institutional investors. 2.5% of Agilon Health shares are owned by insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fulgent Genetics has lower revenue, but higher earnings than Agilon Health. Fulgent Genetics is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilon Health	$5.93B	0.25	-$391.35M	-$14.27	N/A
Fulgent Genetics	$323.93M	1.74	-$60.51M	-$2.82	N/A

Summary

Fulgent Genetics beats Agilon Health on 9 of the 16 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGT vs. The Competition

Export

Metric	Fulgent Genetics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$562.68M	$9.84B	$7.17B	$12.85B
Dividend Yield	N/A	2.61%	2.57%	11.71%
P/E Ratio	-7.25	33.53	274.94	25.33
Price / Sales	1.74	4.89	685.45	111.12
Price / Cash	N/A	125.15	76.65	51.52
Price / Book	0.57	5.29	10.33	6.20
Net Income	-$60.51M	$313.25M	$3.50B	$358.50M
7 Day Performance	3.65%	-1.26%	-3.32%	-2.35%
1 Month Performance	9.30%	-0.98%	-0.41%	-2.77%
1 Year Performance	-6.54%	15.13%	19.21%	7.63%

Fulgent Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGT Fulgent Genetics	3.4708 of 5 stars	$20.45 +1.6%	$27.50 +34.5%	-8.1%	$562.68M	$323.93M	N/A	1,315	Positive News
MD Pediatrix Medical Group	1.5918 of 5 stars	$26.96 -0.3%	$26.60 -1.3%	+57.3%	$2.19B	$1.91B	12.90	4,315	Analyst Upgrade
ASTH Astrana Health	4.0864 of 5 stars	$38.10 -1.0%	$49.43 +29.7%	+25.0%	$2.12B	$3.84B	46.46	3,000	Positive News
GRDN Guardian Pharmacy Services	1.7982 of 5 stars	$42.47 +4.2%	$43.83 +3.2%	+44.9%	$2.11B	$1.45B	41.23	3,600
PGNY Progyny	4.4251 of 5 stars	$27.15 +4.7%	$34.36 +26.6%	+18.0%	$2.08B	$1.31B	29.51	310	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Competitors

FLGT vs. MD, ASTH, GRDN, PGNY, and AGL

How does Fulgent Genetics compare to Pediatrix Medical Group?

Summary

How does Fulgent Genetics compare to Astrana Health?

Summary

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Summary

How does Fulgent Genetics compare to Progyny?

Summary

How does Fulgent Genetics compare to Agilon Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Competitors

FLGT vs. MD, ASTH, GRDN, PGNY, and AGL

How does Fulgent Genetics compare to Pediatrix Medical Group?

Do insiders & institutionals believe in MD or FLGT?

Is MD or FLGT more profitable?

Do analysts rate MD or FLGT?

Does the media favor MD or FLGT?

Which has more volatility & risk, MD or FLGT?

Which has higher earnings and valuation, MD or FLGT?

Summary

How does Fulgent Genetics compare to Astrana Health?

Is ASTH or FLGT more profitable?

Do analysts prefer ASTH or FLGT?

Which has more risk & volatility, ASTH or FLGT?

Do insiders and institutionals believe in ASTH or FLGT?

Does the media prefer ASTH or FLGT?

Which has preferable valuation & earnings, ASTH or FLGT?

Summary

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Is FLGT or GRDN more profitable?

Does the media refer more to FLGT or GRDN?

Do institutionals and insiders hold more shares of FLGT or GRDN?

Which has better valuation and earnings, FLGT or GRDN?

Do analysts recommend FLGT or GRDN?

Which has more risk & volatility, FLGT or GRDN?

Summary

How does Fulgent Genetics compare to Progyny?

Which has more risk and volatility, PGNY or FLGT?

Do institutionals and insiders hold more shares of PGNY or FLGT?

Is PGNY or FLGT more profitable?

Do analysts rate PGNY or FLGT?

Does the media favor PGNY or FLGT?

Which has better earnings & valuation, PGNY or FLGT?

Summary

How does Fulgent Genetics compare to Agilon Health?

Is AGL or FLGT more profitable?

Does the media favor AGL or FLGT?

Which has more risk & volatility, AGL or FLGT?

Do analysts rate AGL or FLGT?

Do institutionals & insiders hold more shares of AGL or FLGT?

Which has higher earnings and valuation, AGL or FLGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools